TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation
Brief Summary: The purpose of the prospective, randomized cohort in this study is to assess the safety and efficacy of 2 apixaban treatment strategies (uninterrupted versus interrupted) in subjects planned to undergo catheter ablation for the treatment of non-valvular atrial fibrillation (NVAF).

Simultaneously, a retrospective cohort of 300 warfarin-treated individuals, identified by chart review, who are matched to the prospective randomized subjects, will be identified. The purpose of the retrospective warfarin cohort is to compare the efficacy and safety of warfarin(the current clinical practice) to that of apixaban (uninterrupted, interrupted, combined uninterrupted and interrupted).


Options:
A: Number of Patients With Clinically-Significant Bleeding (Randomization to 1 month post catheter ablation); Number of Patients With Thrombotic Events (Randomization to 1 month post catheter ablation)
B: Clinically significant hematoma (defined as hematoma requiring reoperation and/or transfusion and/or unplanned or prolonged hospitalization and/or interruption of LMWH or IV heparin or oral anti-coagulant. (Device implant until first routine post-op visit)
C: Absence of thromboembolic events 48 hours post-ablation (48 hours)
D: Composite of recurrence of cerebral infarction, systemic embolism, all-cause death, hospitalization for heart failure. (Up to 6 years)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: The Effects of Short, Frequent Breaks in Sitting Versus Longer, Planned Breaks in Sitting on Sedentary Behavior and Metabolic Health Among Inactive Females Working Sedentary Jobs
Brief Summary: The purpose of this study is to determine whether varying the frequency and length of activity breaks during the workday will differentially impact sedentary behavior and health outcomes. Participants will be randomly assigned to take short, frequent breaks (i.e., 1 minute every half hour) or longer, planned breaks (i.e., two 15-minute walks) from sitting during the workday. They will be instructed to follow the assigned protocols for an 8-week intervention and the effects of their participation on sedentary behavior and a variety of health outcomes will be assessed. The investigators anticipate participants in both intervention arms will demonstrate significant reductions in daily sitting time, bit do not have an a priori hypothesis regarding the relative effectiveness of each approach.


Options:
A: Changes in daily sitting time in hours and minutes (Baseline, 4 months, 10 months and 22 months)
B: Change in sedentary behavior during the workday (Baseline - week 8)
C: Change in total weekly minutes of physical activity as measured by the 7-Day PAR (Physical Activity Recall), from Baseline to 6-months and 12-months. (Baseline, 6 months, and 12 months)
D: Change in length of break from sitting in minutes (baseline, 2, 4, and 6 weeks); Change in frequency of break from sitting in minutes (baseline, 2, 4, and 6 weeks); Change in minutes spent standing (baseline, 2, 4, and 6 weeks); Change in minutes spent in light intensity physical activity (baseline, 2, 4, and 6 weeks); Change in minutes spent in moderate intensity physical activity (baseline, 2, 4, and 6 weeks)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: The Effects of Short, Frequent Breaks in Sitting Versus Longer, Planned Breaks in Sitting on Sedentary Behavior and Metabolic Health Among Inactive Females Working Sedentary Jobs
Brief Summary: The purpose of this study is to determine whether varying the frequency and length of activity breaks during the workday will differentially impact sedentary behavior and health outcomes. Participants will be randomly assigned to take short, frequent breaks (i.e., 1 minute every half hour) or longer, planned breaks (i.e., two 15-minute walks) from sitting during the workday. They will be instructed to follow the assigned protocols for an 8-week intervention and the effects of their participation on sedentary behavior and a variety of health outcomes will be assessed. The investigators anticipate participants in both intervention arms will demonstrate significant reductions in daily sitting time, bit do not have an a priori hypothesis regarding the relative effectiveness of each approach.


Options:
A: Change from control week and intervention week in total energy expenditure (TEE) (week 1 and week 2); Resting energy expenditure (REE) (Baseline (day 0)); Change from control week and intervention week in physical activity energy expenditure (PAEE) (week 1 and week 2); Change from control week and intervention week in daily time spent in sedentary (SB) (week 1 and week 2); Change from control week and intervention week in light (LIPA), moderate and vigorous (MVPA) intensity activities (week 1 and week 2); Change from control week and intervention week in number of breaks in sedentary time (BST) (week 1 and week 2); Change from control week and intervention week in time spent sitting (TSS) (week 1 and week 2); Change from control week and intervention week in time spent standing (TSst) (week 1 and week 2); Change from control week and intervention week in time spent walking (TSW) (week 1 and week 2); Change from control week and intervention week in number of steps (week 1 and week 2)
B: Step Watch - Physical Activity Minutes (12 weeks between baseline and post-intervention follow up)
C: Change from baseline occupational sitting time (minutes/day) at post-intervention (19 weeks) and two months follow-up. (Baseline,19 weeks, two months follow-up); Change from baseline step counts (steps/day) at post-intervention (19 weeks) and two months follow-up (Baseline,19 weeks, two months follow-up)
D: Change in sedentary behavior during the workday (Baseline - week 8)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: The Effects of Short, Frequent Breaks in Sitting Versus Longer, Planned Breaks in Sitting on Sedentary Behavior and Metabolic Health Among Inactive Females Working Sedentary Jobs
Brief Summary: The purpose of this study is to determine whether varying the frequency and length of activity breaks during the workday will differentially impact sedentary behavior and health outcomes. Participants will be randomly assigned to take short, frequent breaks (i.e., 1 minute every half hour) or longer, planned breaks (i.e., two 15-minute walks) from sitting during the workday. They will be instructed to follow the assigned protocols for an 8-week intervention and the effects of their participation on sedentary behavior and a variety of health outcomes will be assessed. The investigators anticipate participants in both intervention arms will demonstrate significant reductions in daily sitting time, bit do not have an a priori hypothesis regarding the relative effectiveness of each approach.


Options:
A: Step Watch - Physical Activity Minutes (12 weeks between baseline and post-intervention follow up)
B: Change in objective measure of degree of physical activity (baseline, 12 weeks, 6 months)
C: Reduced total time spend sitting at work (1 month); Reduced number of prolonged siting periods (>30 min) (1 month); Increased number of breaks from sitting time (1 month)
D: Change in sedentary behavior during the workday (Baseline - week 8)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Targeted Parasite Elimination in the Human and Mosquito to Reduce Malaria Transmission: A Cluster Randomised Controlled Factorial Design Trial of Reactive Focal Drug Administration (rfMDA) Versus Reactive Case Detection (RACD), With and Without Reactive Vector Control (RAVC), From the Low Endemic Setting of Namibia
Brief Summary: This is a cluster randomised controlled trial with factorial study design comparing the impact of reactive community-based malaria interventions: 1) presumptive treatment (or rfMDA, reactive focal mass drug administration) versus reactive case detection (RACD), and 2) reactive IRS (indoor residual spraying) versus control on the incidence of malaria in Namibia.


Options:
A: Difference in prevalence of malaria infection in children 0.5-14 years between intervention arms (up to 36 months); Difference in Entomological Inoculation Rate (up to 36 months)
B: Decrease in Parasite prevalence according to RDT (6 months); Decrease in Parasite prevalence according to PCR (6 months); Total and confirmed outpatient (OPD) malaria case incidence and inpatient (IPD) malaria case incidence among all ages (12 months)
C: Incidence (Up to 12 months)
D: Cost per case averted in children five years of age and under at health facility level by adding Actellic-IRS (24 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Acceptability and Feasibility of Micronutrient Powders Versus Iron Syrup for Anemia Prevention in Young Children
Brief Summary: This study seeks to assess the acceptability, compliance, and preference for iron supplementation; micronutrient powders (MNP) versus iron syrup. Additionally, this study seeks to assess front line health worker perceptions and experiences regarding ease of implementation of each strategy and delivery strategy preference.


Options:
A: Product sales and use (coverage) (Every 2 weeks)
B: Acceptability of iron and folic acid (IFA) syrup (Endline (Up to 5 months)); Acceptability of micronutrient powders (MNP) (Endline (Up to 5 months)); Preference for vitamin supplementation (Endline (Up to 5 months)); Vitamin supplementation compliance (Baseline, Endline (Up to 5 months))
C: child nutritional status (Burundi: 2 years; Guatemala: at pregnancy, 1 mo, 4 mo, 6 mo, 9 mo, 12 mo, 18 mo, 24 mo)
D: "negative nutritional outcome" of a child (6 months follow-up)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: The Effect of Replacement of Vitamin K Antagonist by Rivaroxaban With or Without Vitamin K2 Supplementation on Vascular Calcifications in Chronic Hemodialysis Patients: A Randomized Controlled Trial
Brief Summary: This study examines patients on chronic hemodialysis with non-valvular atrial fibrillation, who have a CHA2DS2-VASc Score of ≥ 2 and therefore are candidates for or already receive a vitamin K antagonist.

The first question is whether replacement of the vitamin K antagonist by rivaroxaban is able to slow progression of vascular calcification. The second question is whether addition of vitamin K2 to rivaroxaban can further slow down or even halt the progression of vascular calcification.


Options:
A: Levels of osteoprotegerin after administration of UFH or LMWH used as anticoagulant therapy for hemodialysis (during and after dialysis sessions)
B: Number of patients with severe bleeding (6 month)
C: absolute and relative change in coronary artery calcification score (18 months); absolute and relative change in thoracic aortic calcification score (18 months); absolute and relative change in pulse wave velocity (18 months)
D: thromboprophylaxis of catheter induced thrombosis (6 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Do Technology Apps Improve Compliance in Adolescent Renal Transplant Recipients?
Brief Summary: The purpose of this study is to empower adolescent renal transplant recipients to fully understand their medical condition as well as to help them acquire the skills to maintain a healthy allograft well into adulthood. It is hoped that introducing technological applications (apps) will assist adolescents in managing medications, clinic appointments, lab appointments, and in tracking fluid intake, blood pressure, caloric intake, and exercise frequency. The investigators aim to improve adolescent post-renal transplant outcomes (increase medication adherence, lower clinic and laboratory no-show rate, lower blood pressure and BMI, maintain creatinine clearance, decrease proteinuria, decrease incidence of allograft rejection, decrease hospitalizations) as well as reduce cost.


Options:
A: change from baseline BMI at 8 months (8th month)
B: Medication Adherence (six months)
C: Medication Adherence Change from Baseline to 6 Months (6 months); Medication Adherence Change from 6 Months to 12 Months (12 months); Medication Adherence Change from Baseline to 12 Months (12)
D: Compliance (1 year)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Evaluation of Video Laryngoscopy (Video Macintosh-blade) and Direct Laryngoscopy (EMMA-Study): A Prospective, Randomized Trial
Brief Summary: A randomized controlled prospective study of laryngoscopy and intubation success comparing direct laryngoscopy and the McGrath® Mac videolaryngoscope.


Options:
A: Proportion of successful orotracheal intubation at first laryngoscopy (intubation procedure, an expected average of 15 minutes)
B: intubation success (at intubation; < 120 seconds)
C: Best view of the glottic structures (120 seconds after induction of narcosis)
D: Delta NoL (From 30 seconds before to 3 minutes after each laryngoscopy (3 total) for each patient)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: FIRST-ABC Feasibility Study: Feasibility Study for a Randomised Trial of High Flow Nasal Cannula (HFNC) Versus Continuous Positive Airway Pressure (CPAP) for Non-invasive Respiratory Support in Critically Ill Children
Brief Summary: A feasibility study to inform the design and conduct of a randomised controlled trial of high flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non-invasive respiratory support in critically ill children


Options:
A: Mean esophageal pressure (3.5 hours)
B: Number of participants with HFNC success (during hospitalization, approximatly 6 days); Number of participants with CPAP/NPPV success (during hospitalization, approximatly 6 days)
C: Number of eligible patients in Group A (step-up) and Group B (step-down) (Baseline); Number of parents/guardians who refuse prospective or deferred consent (Through study completion, an average of 24 hours); Randomising at least 50% of eligible patients (Baseline); Proportion of patients adherent to the study treatment (Through study completion, an average of 72 hours); Mean COMFORT score (72 hours); Number of parents completing the Parental Stressor Scale: PICU (PSS:PPICU) (24 hours)
D: Difference in mean Respiratory Assessment Change Score (RACS) between groups in every time considered (Every 4h for three consecutive times beginning in the moment of inclusion in the study and after every 8h for three consecutive times (average of 36h))

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: PROVEN: Pragmatic Trial of Video Education in Nursing Homes
Brief Summary: This is a pragmatic cluster-randomized control trial (RCT) of an Advance Care Planning (ACP) Video Program for nursing home (NH) patients ≥ 65 years old who are cared for in 360 NH facilities (intervention arm n=119; control arm n=241) within two NH health care systems: Genesis HealthCare and PruittHealth. The intervention NH facilities will implement the ACP Video Program, while the control NH facilities will follow their usual ACP procedures. The trial will evaluate the effectiveness of the ACP Video Program by comparing hospitalizations, advance directives, and hospice use in the intervention vs. control NHs.


Options:
A: Changes in Neuropsychiatric Inventory (24 weeks); Changes in Cornell's Depression Scale (24 weeks); Changes in UPDRS subscale (24 weeks)
B: Change in scores from baseline to week 26 on measuring cognition Severe Impairment Battery test and the Minimum Data Set Activities of Daily Living test.
C: Documented Decisions to Forgo Hospitalization (by six months)
D: Hospital Transfer Rate in Target Cohort (12-month observation period)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients
Brief Summary: Scheduled, low-dose quetiapine is effective in preventing delirium in high-risk critically ill, trauma/surgical patients. Prophylaxis also reduced ventilator duration and ICU length of stay.


Options:
A: N/A
B: the rate of hematological remission; the rate of molecular remission; the kinetics of the MRD of PML/RARa during and after ATO
C: delirium (during admission at the critical care)
D: Incidence of delerium (One year)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: RELAX: A Mobile Application Suite Targeting Obesity and Stress
Brief Summary: This research is being done is to evaluate the feasibility and acceptability of a novel weight loss mobile app that was designed to be less burdensome than traditional weight loss apps.


Options:
A: Percentage of Days App Used Over 12 Weeks (12 weeks); Usability (12 weeks); Acceptability (12 weeks); Burden (12 weeks)
B: Weight loss (12 weeks)
C: Percent weight loss: objective (Baseline, 6 Months); Weight (Baseline, 6 Months)
D: Percent Change in Body Weight From Baseline to 12 Weeks (12 weeks)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Feasibility of Melatonin for Prevention of Delirium in Critically Ill Patients: a Multi-centre, Randomized, Placebo-controlled Study.
Brief Summary: The purpose of this study is to determine the feasibility of conducting a randomized controlled trial (RCT) with melatonin for prevention of delirium in critically ill adult patients. The investigators hypothesize that melatonin, administered on a scheduled nightly basis during ICU admission, will be efficacious and safe for the prevention of delirium in critically ill adults.


Options:
A: Duration of Mechanical Ventilation (ICU stay)
B: Feasibility: Study adherence (1 year)
C: the rate of hematological remission; the rate of molecular remission; the kinetics of the MRD of PML/RARa during and after ATO
D: Cognitive function (3 months after discharge from ICU)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: With the dissatisfaction of monoamine-based pharmacotherapy and the high comorbidity of physical illness in depression, the serotonin hypothesis seems to fail in approaching the etiology of depression. Based upon the evidence from epidemiological data, case-control studies of PUFAs compositions, and antidepressant effects in clinical trials, phospholipid polyunsaturated fatty acids (PUFAs) is enlightening a promising path to discover the unsolved of depression.


Options:
A: Change in BDI-II Depressive Symptom Scores (8 weeks)
B: Changes from Baseline Hamilton Depression Rating Scale (HDRS) at 12 weeks (Week 12); Remission rate (Week 12); Response rate (Week 12)
C: Percentage of Participants with major depressive episode (for Study 1); Changes in Hamilton Depression Rating Scale (HDRS) (for Study 2) (Weeks 0 to 24)
D: Hamilton Depression Rating Scale 17 (HDRS-17) Scores (Baseline, Weeks 1, 2, 4, 6, 8, 10 and 12)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Effect on Attendance if Including Focused Information of Spirometry in Preventive Health Checks - a Randomized Controlled Trial in Primary Health Care
Brief Summary: The purpose of this study is to investigate if focused information of spirometry in the invitation to preventive health checks will increase the attendance compared with a standard invitation to preventive health checks.


Options:
A: Cardiovascular mortality (Sept 2010); MI (non fatal) (Sept 2010); Stroke (non fatal) (Sept 2010); Revascularisation (operating procedures) (Sept 2010); Amputations, non traumatic (Sept 2010)
B: All cause mortality (3, 5, and 10 years)
C: The percentage of participants attending the health check compared between the groups (one-year recruitment)
D: Composite outcome of multiple cardiovascular risk factors (2 year)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Postprandial Effect of Breakfast Glycemic Index on Vascular Function, Insulinemia and Cognitive Performance, a Crossover Clinical Trial (BGI Study)
Brief Summary: This is a crossover clinical trial aimed at adults (aged 20-40 years, with no cardiovascular disease), selected by consecutive sampling at urban primary care health clinics in Salamanca (Spain). Each subject will complete three interventions, with a washout period of one week: control breakfast (water), low glycemic index breakfast (apple, yogurt, walnuts and black chocolate) and high glycemic index breakfast (grape juice, bread and strawberry jam). The postprandial effect will be assessed at 60 and 120 minutes from each breakfast, measuring blood glucose and insulin and cognitive performance. Measurements will be performed of central blood pressure, augmentation index, pulse wave velocity, cardiac output and total peripheral vascular resistance at minutes (-10, 0, +15, +30, +45, +60, +75, +90, +105 and +120).


Options:
A: Endothelial function (Time points: day 0 [baseline], and day 30 each 0 and 2h.)
B: Changes in systolic and diastolic blood pressure (8 weeks)
C: Augmentation index (Changes in augmentation index at 1 week, according to glycemic index of the breakfast)
D: An improvement of endothelial function as measured by flow-mediated dilation (FMD) (1 month)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Comparison of the Prophylactic Anti-emetic Efficacy of Gabapentin and Ramosetron in Patients Undergoing Laparoscopic Gynecological Surgery
Brief Summary: This study was designed to compare the effects of gabapentin and ramosetron on PONV in patients undergoing laparoscopic gynecologic surgery.


Options:
A: Incidence of postoperative nausea and vomiting (48 hours postoperative)
B: Pain score by numeric rating scale (At 8 hours postoperatively)
C: Cumulative 24 Hour Oral Morphine Equivalent Consumption (24 hours (Day 1))
D: Number of Participants Experiencing Postoperative Nausea and Vomiting in 24h Postoperatively (within 24h after operation)

Answer: A